ELV — Elevance Health Inc.

Elevance Health (ELV) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• GAAP Diluted EPS: $5.32
• Adjusted Diluted EPS: $6.03
• Total Operating Revenue: $50.1 billion, up 12% year-over-year, driven by higher premium yields and Medicare Advantage membership growth.
• Medical Membership: 45.4 million, with Medicaid membership concentrated among lower acuity members.
• Consolidated Benefit Expense Ratio: 91.3%, aligned with expectations.
• Operating Cash Flow: $1.1 billion, impacted by a cash settlement related to litigation.
• Share Repurchases: $875 million, reflecting a disciplined capital deployment strategy.

2. Strategic Updates and Business Highlights

• Focus on Cost Management: Elevance is leveraging value-based care and integrated clinical approaches to reduce overall care costs and improve member experience.
• Carelon Growth: Carelon's external revenue grew double digits, with Carelon Rx revenue up 20% year-over-year and Carelon Services growing over 50%.
• Medicare Advantage Improvements: Approximately 55% of MA members will be in 4-star or higher contracts for the 2027 payment year, up from 40% in 2026.
• AI Integration: More than 10 million members will have access to an AI-enabled virtual assistant by year-end, aimed at enhancing member engagement and operational efficiency.

3. Forward Guidance and Outlook

• 2025 Adjusted EPS Guidance: Reaffirmed at approximately $30, with a baseline of $27 excluding nonrecurring items.
• 2026 Planning Assumptions: Expecting at least a 125 basis point decline in Medicaid margins due to elevated acuity and utilization trends.
• Long-term Growth Outlook: Anticipating a return to balanced earnings growth in 2027, with improvements in Medicaid margins and sustained momentum in Carelon and commercial segments.

4. Bad News, Challenges, or Points of Concern

• Medicaid Margin Pressure: Full-year 2025 Medicaid operating margin expected to be slightly negative, with further declines anticipated in 2026 due to misalignment of rates and acuity.
• Membership Declines: Anticipated modest decline in Medicaid membership in 2026 due to ongoing reverification processes and state program changes.
• Regulatory Risks: Potential expiration of enhanced ACA subsidies could significantly impact membership and revenue in the ACA market.
• Cost Trends: Elevated utilization trends across various segments, including behavioral health and inpatient services, continue to pressure margins.

5. Notable Q&A Insights

• Medicaid Discussions with States: Management is actively engaging with states on rate adequacy and program changes, with states showing receptivity to cost-reduction strategies.
• Investment Spending: Several hundred million dollars will be invested in technology, Carelon capabilities, and operational initiatives to support long-term growth.
• Medicare Strategy: The focus remains on HMO and dual-eligible products, with a strategic pullback from PPO offerings to enhance profitability and manage member care effectively.
• Coding Trends: Management is addressing increased coding intensity with providers to ensure accurate documentation and compliance, which will support financial performance.

Overall, Elevance Health's Q3 2025 results reflect solid execution amidst a challenging healthcare landscape, with a focus on long-term strategic initiatives while navigating headwinds in the Medicaid segment and potential regulatory changes.